Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Hypertriglyceridemia · Type 2 Diabetes Mellitus · IONS

IONIS PHARMACEUTICALS

IONIS PHARMACEUTICALS INC

IONIS PHARMACEUTICALS clinical programs — 33 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
2855 Gazelle Ct, Carlsbad, CA 92010, US HQ
1989 Founded
1,493 Employees
Public company Type
IONS · NYSE Ticker
Company details
Status
Public
HQ
2855 Gazelle Ct, Carlsbad, CA 92010, US
Founded
1989
Employees
1,493
Programs
128
Drugs
48
Patents
222
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

IONIS PHARMACEUTICALS projects

33 ClinicalTrials.gov programs sponsored by IONIS PHARMACEUTICALS.

IONIS PHARMACEUTICALS has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

33 programs

Clinical programs

  1. Alicaforsen

    IONIS PHARMACEUTICALS INC

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  2. Donidalorsen

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  3. Donidalorsen

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 3 small molecule active

    4 trials

  4. Eplontersen

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  5. Eplontersen

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    phase 3 small molecule active

    2 trials

  6. ION 682884, ION 682884

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  7. ION-682884-CS2

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

    phase 3 small molecule active

    1 trial

  8. ION363

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  9. ION363-CS1

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations

    phase 3 small molecule active

    1 trial

  10. ION582

    IONIS PHARMACEUTICALS INC

    Angelman Syndrome

    phase 3 small molecule active

    2 trials

  11. ION582

    IONIS PHARMACEUTICALS INC

    Angelman syndrome

    phase 3 small molecule active

    1 trial

  12. ISIS 3521

    IONIS PHARMACEUTICALS INC

    Lung Cancer

    phase 3 mab completed

    1 trial

  13. ISIS 678354

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    1 trial

  14. ISIS 678354-CS13

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  15. ISIS 678354-CS5

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia.

    phase 3 small molecule active

    1 trial

  16. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  17. ISIS 721744, ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  18. Inotersen

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule completed

    1 trial

  19. Inotersen

    IONIS PHARMACEUTICALS INC

    FAP

    phase 3 small molecule completed

    2 trials

  20. Mipomersen

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  21. Mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  22. Olezarsen

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia

    phase 3 small molecule completed

    3 trials

  23. Olezarsen

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    3 trials

  24. Olezarsen

    IONIS PHARMACEUTICALS INC

    Hypertriglyceridemia

    phase 3 small molecule completed

    2 trials

  25. Tofersen

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  26. Tofersen

    IONIS PHARMACEUTICALS INC

    ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

    phase 3 small molecule completed

    1 trial

  27. Volanesorsen

    IONIS PHARMACEUTICALS INC

    Hypertriglyceridemia

    phase 3 small molecule completed

    1 trial

  28. Volanesorsen

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule completed

    2 trials

  29. mipomersen

    IONIS PHARMACEUTICALS INC

    Lipid Metabolism, Inborn Errors

    phase 3 small molecule completed

    2 trials

  30. mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  31. mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Lipid Metabolism, Inborn Errors

    phase 3 small molecule completed

    2 trials

  32. volanesorsen

    IONIS PHARMACEUTICALS INC

    Familial Partial Lipodystrophy

    phase 3 small molecule terminated

    1 trial

  33. zilganersen

    IONIS PHARMACEUTICALS INC

    Alexander Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does IONIS PHARMACEUTICALS have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.